6MW-3211 is under clinical development by Mabwell Shanghai Bioscience and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 6MW-3211’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
6MW-3211 is under development for the treatment of advanced malignancy tumors, relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), extensive-stage small cell lung cancer, non-small cell lung cancer, relapsed and refractory lymphoma and renal cell carcinoma and solid tumor. It is administered through parenteral, intravenous and intravenous drip route. The drug candidate is a recombinant, humanized bi-specific monoclonal antibody acts by targeting leukocyte surface antigen CD47 and programmed cell death Ligand 1 (PD L1). It is being developed based on bi-specific/bi-functional antibody development platform.
Mabwell Shanghai Bioscience overview
Mabwell Shanghai Bioscience is a company that is focused on the discovery and industrialization of therapeutic monoclonal antibody, innovative vaccines and long-acting cytokine drugs. The company is headquartered in Shanghai, China.
For a complete picture of 6MW-3211’s drug-specific PTSR and LoA scores, buy the report here.